Wikidata

(Q62034414)

English

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity

clinical trial

In more languages

Statements

title
A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity (English)
0 references
medical condition
syndrome
0 references
obesity
0 references
Laurence-Moon syndrome
0 references
Alström syndrome
0 references
Bardet-Biedl syndrome
0 references
main subject
obesity
0 references
start time
10 December 2018
0 references
end time
30 June 2020
0 references
number of participants
30
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q62034414&oldid=1857027253"